Rising Incidence of Ischemic Reperfusion Injury to Augment the Ischemia Reperfusion Injury Therapeutics Market Growth



 Ischemic reperfusion injury occurs due to the insufficient blood supply to the tissue. Ischemia reperfusion injury is the tissue damage caused when blood supply returns to tissue after a period of ischemia or lack of oxygen. Moreover, it is a critical medical condition that poses a major therapeutic challenge for physicians. Potential therapies include ischemic preconditioning, pharmacological treatment, and vitamin therapy or the use of medical gases, which could significantly help develop strategies to prevent ischemia reperfusion injury.

Market Dynamics:

Increasing incidence/prevalence of cardiovascular diseases, such as myocardial infarction and stroke, worldwide is expected to propel the growth of the ischemia reperfusion injury therapeutics market. For instance, according to the World Health Organization, cardiovascular diseases are the leading cause of death worldwide, accounting for around 17.9 million lives each year.

Moreover, increasing number of tissue damage cases and growing awareness among people about treatment of ischemia and reperfusion injury is expected to augment the growth of the ischemia reperfusion injury therapeutics market.

Introduction of novel drugs, increasing product approvals, and rising research and development activities are also expected to fuel the growth of the ischemia reperfusion injury therapeutics market. For instance, in January 2021, the United States Food and Drug Administration (FDA) approved Faron Pharmaceuticals’ New Drug Application for Traumakine, which can be used to prevent systemic inflammatory response syndrome, which could be caused by noninfectious insults such as ischemia-reperfusion injury.

Moreover, the increasing incidence of ischemic reperfusion injury worldwide and strategic partnerships and collaborations of major players are expected to drive the ischemia reperfusion injury therapeutics market growth.

Competitive Analysis:

Major players operating in the ischemia reperfusion injury therapeutics market are Gilead Sciences, Ensemble Therapeutics Corporation, Erimos Pharmaceuticals, Curatis Pharma GmbH, Biomedica Management Corporation, Bolder Biotechnology, Bayer AG, Angion Biomedica Corp., Antipodean Pharmaceuticals, Amyndas Pharmaceuticals LLC, Stealth BioTherapeutics Inc., Zealand Pharma A/S, Prothix BV, Prolong Pharmaceuticals, Proteo, PledPharma AB, Orexo, Pharming Group N.V., Opsona Therapeutics Limited, Nyken B.V., and Omeros Corporation.

Major players in the market are focused on adopting various strategies, such as partnerships and collaborations, to develop advanced drugs and treatment in the market. For instance, in December 2020, LUCA Science announced that it will collaborate with the Division of Cardiology, Field of Internal Medicine, Nagoya University Graduate School of Medicine to initiate a joint research on the development of mitochondrial therapy for cardiac ischemic–reperfusion injury.

Comments

Popular posts from this blog

Bourbon Whiskey Is the Most Popular Whiskey in America and In Many Other Countries around the World

Viral Vectors And Plasmid DNA Manufacturing Market Is Gaining Major Traction With Oxford Biomedica Plc Entering Into A 3-Year Agreement With Boehringer Ingelheim For The Manufacture And Supply Of Various Types Of Viral Vectors

Hard Surface Flooring Market Is Expected To Witness Robust Growth As Mohawk Industries Introduces Newly Imagined 30,000-Square Foot Floor Space At The International Surface Event (TISE)